Products

Kyprolis 60mg Injection (Carfilzomib): The Gold Standard Proteasome Inhibitor for Multiple Myeloma Kyprolis 60 mg Injection is a sophisticated antineoplastic agent containing the active substance Carfilzomib. As a second-generation proteasome inhibitor, Kyprolis is engineered for higher selectivity and more potent anti-tumor activity compared to earlier treatments. Manufactured by Amgen, it is a vital therapeutic intervention for patients with multiple myeloma, particularly those who have developed resistance to other therapies. Therapeutic Indications and Clinical Usage Kyprolis 60 mg is a cornerstone in international hematological oncology for the treatment of: Relapsed or Refractory Multiple Myeloma (RRMM): Specifically for adult patients who have received one to three prior lines of therapy. Combination Regimens: * Kd Regimen: Combined with Dexamethasone. KRd Regimen: Combined with Lenalidomide and Dexamethasone. DKd Regimen: Combined with Daratumumab and Dexamethasone. Superior Progression-Free Survival: Clinical trials have demonstrated that Kyprolis-based regimens significantly extend survival compared to standard-of-care treatments in relapsed settings. Mechanism of Action: How Kyprolis 60mg Works Irreversible Proteasome Binding: Carfilzomib binds irreversibly to the chymotrypsin-like activity of the 20S proteasome. Inhibition of Protein Degradation: The proteasome is the cell's “shredder“ for damaged proteins. Blocking it causes an immediate, toxic buildup of polyubiquitinated proteins. Induction of Apoptosis: Myeloma cells produce vast amounts of protein (M-protein); when their “waste disposal“ is blocked, they experience overwhelming cellular stress, leading to programmed cell death (apoptosis). Targeted Efficiency: Kyprolis is designed to minimize off-target binding, which is why it often presents a lower incidence of peripheral neuropathy compared to first-generation inhibitors like bortezomib. Dosage and Administration Guidelines Administration: Kyprolis 60 mg is administered strictly via intravenous (IV) infusion by clinical professionals. Infusion Time: Depending on the dose and regimen, infusions typically last 10 minutes or 30 minutes. Cycle Intensity: Usually administered on two consecutive days each week for three weeks, followed by a 12-day rest period (28-day cycle). Pre-Treatment Hydration: Adequate oral and IV hydration is mandatory before and after the first cycle to prevent Tumor Lysis Syndrome (TLS) and protect renal function. Safety Profile and Professional Monitoring Cardiac & Pulmonary Health: Monitoring for signs of heart failure, hypertension, or pulmonary hypertension. Renal Function: Regular serum creatinine monitoring is essential, as the medication is processed through the kidneys. Hematological CBC: Periodic blood counts are necessary to manage potential thrombocytopenia (low platelets) or anemia. Common Side Effects: Fatigue, nausea, fever, headache, and diarrhea are frequently reported and managed with supportive care. Strict Cold-Chain Storage & Global Handling Temperature Sensitivity: Kyprolis is a sensitive biologic and MUST be stored refrigerated between 2°C and 8°C (36°F to 46°F). Handling: Do not freeze the vial. Keep it in the original carton to protect it from light. Logistical Security: For global export, we utilize validated thermal packaging and real-time data loggers to ensure the medication remains within the required temperature range throughout transit. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Mylocar 60mg Injection (Carfilzomib): Advanced Proteasome Therapy for Multiple Myeloma Mylocar 60mg Injection is a potent, targeted antineoplastic therapy containing the active ingredient Carfilzomib. As a second-generation proteasome inhibitor, Mylocar is designed to provide deeper and more durable clinical responses in patients battling plasma cell malignancies. It is primarily utilized in specialized oncology settings to treat relapsed or refractory cases where previous therapies have failed to contain the disease. Therapeutic Indications and Clinical Usage Mylocar 60mg is a critical component in modern hematological oncology protocols, particularly for: Relapsed Multiple Myeloma: For adult patients whose cancer has returned after a period of remission. Refractory Multiple Myeloma: For patients whose cancer no longer responds to standard treatments like bortezomib or immunomodulatory agents. Combination Protocols: Often prescribed in synergy with Dexamethasone or a combination of Lenalidomide and Dexamethasone to maximize the destruction of malignant cells. Mechanism of Action: How Mylocar 60mg WorksProteasome Inhibition: The medication binds irreversibly to the 20S proteasome, an enzyme complex that breaks down unneeded proteins within the cell. Protein Toxicity: By blocking this “waste disposal“ system, Mylocar causes a rapid, toxic buildup of proteins inside the myeloma cell. Cellular Apoptosis: This imbalance creates severe cellular stress, forcing the cancer cell to undergo apoptosis (programmed cell death). Selective Impact: Because myeloma cells produce large amounts of protein (antibodies), they are significantly more sensitive to proteasome inhibition than healthy cells. Dosage and Administration Guidelines Administration: Mylocar 60mg must be administered as an intravenous (IV) infusion by a qualified medical professional. Infusion Time: Depending on the specific regimen, the infusion typically lasts between 10 to 30 minutes. Cycle Schedule: Treatment is usually given in 28-day cycles. In a standard cycle, the injection is administered on two consecutive days each week for three weeks, followed by a 12-day rest period. Patient Hydration: It is vital for patients to remain well-hydrated before and after administration to protect kidney function and prevent Tumor Lysis Syndrome (TLS). Safety Profile and Clinical Monitoring Cardiac and Pulmonary Health: Monitoring for signs of heart failure, high blood pressure, or shortness of breath (pulmonary hypertension). Hematological Checks: Regular blood tests are required to monitor for anemia, neutropenia (low white blood cells), and thrombocytopenia (low platelets). Kidney and Liver Function: Periodic lab tests (Creatinine, liver enzymes) ensure the organs are processing the medication safely. Common Side Effects: These may include fatigue, nausea, fever, and diarrhea. Strict Cold-Chain Storage & Global Handling Temperature Sensitivity: Mylocar 60mg is a temperature-sensitive medication and MUST be stored refrigerated between 2°C and 8°C (36°F to 46°F). Light Protection: Vials should be kept in their original carton to avoid degradation from light. Safe Transit: For international shipping, we utilize specialized cold-chain logistics, including thermal packaging and real-time temperature tracking, to ensure the medication remains potent. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Kyfil 30mg Injection (Carfilzomib): Advanced Proteasome Inhibitor for Refractory Multiple Myeloma Kyfil 30mg Injection is a high-potency antineoplastic agent featuring the active pharmaceutical ingredient Carfilzomib. As a second-generation proteasome inhibitor, Kyfil 30mg is a critical therapeutic intervention in modern hematological oncology, specifically engineered to overcome resistance in patients with multiple myeloma. Manufactured by Biocon, a global leader in biopharmaceuticals, Kyfil provides a targeted mechanism to disrupt cancer cell survival while minimizing the peripheral neuropathy often associated with first-generation treatments. Therapeutic Indications and Clinical Usage Kyfil 30mg is widely utilized in international oncology centers for the management of aggressive blood cancers: Relapsed or Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least one to three prior lines of therapy. Combination Therapy: Frequently prescribed in combination with Dexamethasone (Kd regimen) or with both Lenalidomide and Dexamethasone (KRd regimen) to achieve superior clinical response rates and prolonged progression-free survival. Monotherapy: Used as a standalone treatment for patients whose disease has progressed after receiving at least two prior therapies, including bortezomib and an immunomodulatory agent. Mechanism of Action: How Kyfil 30mg Works Irreversible Inhibition: Carfilzomib binds irreversibly to the 20S proteasome, the enzyme complex responsible for degrading damaged or unneeded proteins within the cell. Proteotoxic Stress: By blocking the proteasome, Kyfil causes a toxic accumulation of polyubiquitinated proteins inside the myeloma cell. Apoptosis Induction: This protein overload triggers a massive cellular stress response, leading directly to apoptosis (programmed cell death). Selective Targeting: Kyfil is designed to be more selective for the proteasome than earlier inhibitors, which contributes to its improved safety profile regarding nerve damage and neurotoxicity. Dosage and Administration Guidelines Route of Administration: Kyfil 30mg is administered strictly as an intravenous (IV) infusion. Infusion Duration: The infusion typically lasts between 10 to 30 minutes, depending on the specific dosage and treatment cycle. Cycle Schedule: Administered on a specific cycle (often a 28-day cycle), typically on two consecutive days each week for three weeks, followed by a 12-day rest period. Hydration Protocol: To mitigate the risk of renal toxicity and Tumor Lysis Syndrome (TLS), patients must be adequately hydrated (both oral and IV) before and after each dose. Safety Profile and Clinical Monitoring Cardiac Monitoring: Patients must be monitored for signs of heart failure or myocardial ischemia. Respiratory Vigilance: Any shortness of breath or cough should be reported immediately, as Kyfil can occasionally cause pulmonary hypertension. Renal Function: Regular monitoring of serum creatinine and electrolyte levels is mandatory to ensure kidney health. Hematological CBC: Periodic blood counts are necessary to monitor for thrombocytopenia (low platelets) and neutropenia. Storage and Global Handling (Cold Chain Management) Temperature Control: Kyfil 30 mg vials MUST be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Handling: Do not freeze. Keep the vial in the original carton to protect it from light. Reconstitution: Once reconstituted, the solution should be used immediately or stored refrigerated for a very short duration as per strict clinical guidelines. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Kyfil 10 mg Injection (Carfilzomib): Advanced Proteasome Inhibitor for Refractory Multiple Myeloma Kyfil 10mg Injection is a high-precision antineoplastic agent containing the active pharmaceutical ingredient Carfilzomib. As a second-generation proteasome inhibitor, Kyfil 10mg is a cornerstone in modern hematological oncology, specifically engineered to overcome resistance in patients with multiple myeloma. Manufactured by Biocon, a global biopharmaceutical leader, Kyfil provides a targeted mechanism to disrupt cancer cell survival while minimizing the peripheral neuropathy often associated with earlier treatments. Therapeutic Indications and Clinical Usage Kyfil 10 mg is utilized in international oncology centers for the management of aggressive blood cancers: Relapsed or Refractory Multiple Myeloma (RRMM): Indicated for adult patients who have received at least one to three prior lines of therapy. Combination Therapy: Frequently prescribed in combination with Dexamethasone (Kd regimen) or with both Lenalidomide and Dexamethasone (KRd regimen) to maximize clinical response rates. Monotherapy: Used as a standalone treatment for patients whose disease has progressed after receiving at least two prior therapies, including bortezomib and an immunomodulatory agent. Mechanism of Action: How Kyfil 10mg WorksIrreversible Inhibition: Carfilzomib binds irreversibly to the 20S proteasome, the enzyme complex responsible for degrading damaged or unneeded proteins within the cell. Protein Overload: By blocking the proteasome, Kyfil causes a toxic buildup of “junk“ proteins inside the myeloma cell. Apoptosis Induction: This protein accumulation triggers a massive cellular stress response, leading directly to apoptosis (programmed cell death). High Selectivity: Kyfil is designed to be more selective for the proteasome than first-generation inhibitors, which contributes to its improved safety profile regarding nerve damage. Dosage and Administration Guidelines Route of Administration: Kyfil 10mg is administered strictly as an intravenous (IV) infusion. Infusion Duration: The infusion usually lasts between 10 to 30 minutes, depending on the specific dosage and cycle. Cycle Schedule: Typically administered on two consecutive days each week for three weeks, followed by a 12-day rest period (a 28-day cycle). Hydration Protocol: To prevent renal toxicity and Tumor Lysis Syndrome (TLS), patients must be adequately hydrated (both oral and IV) before and after the dose. Safety Profile and Clinical Monitoring Cardiac Monitoring: Patients should be monitored for new or worsening heart failure or myocardial ischemia. Respiratory Vigilance: Any shortness of breath should be reported immediately, as Kyfil can occasionally cause pulmonary hypertension or acute respiratory distress. Renal Function: Regular monitoring of serum creatinine levels is mandatory to ensure kidney health during treatment. Hematological CBC: Regular blood counts are necessary to monitor for thrombocytopenia (low platelets) and neutropenia. Storage and Global Handling (Cold Chain) Temperature Control: Kyfil 10mg vials MUST be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Handling: Do not freeze. Keep the vial in the original carton to protect it from light. Reconstitution: Once reconstituted, the solution should be used immediately or stored refrigerated for a very short duration as per clinical guidelines. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Tevimbra 100 mg Injection is a cutting-edge immunotherapy containing the active biological agent Tislelizumab. As a humanized monoclonal antibody designed to block the Programmed Death Receptor-1 (PD-1), Tevimbra represents a significant breakthrough in the treatment of advanced malignancies. Originally developed by BeiGene and launched in major global markets including India (marketed by Glenmark), Tevimbra is engineered to help the body’s own immune system identify and eliminate cancer cells more effectively. Therapeutic Indications and Clinical Usage Tevimbra 100mg is approved for several high-impact oncology indications across international regulatory frameworks (FDA, EMA, TGA): Esophageal Squamous Cell Carcinoma (ESCC): * First-Line: Used in combination with platinum-based chemotherapy for patients with unresectable, locally advanced, or metastatic ESCC. Monotherapy: Indicated as a single agent for adults with unresectable or metastatic ESCC who have previously received systemic chemotherapy (not including prior PD-L1 inhibitors). Gastric and Gastroesophageal Junction (G/GEJ) Cancer: Indicated in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of HER2-negative advanced or metastatic gastric cancer expressing PD-L1. Non-Small Cell Lung Cancer (NSCLC): Approved in various regions for the treatment of locally advanced or metastatic NSCLC, either as a standalone therapy or in combination with chemotherapy protocols. Nasopharyngeal Carcinoma (NPC): Utilized in combination with gemcitabine and cisplatin for recurrent or metastatic NPC. Mechanism of Action: How Tevimbra 100mg Works PD-1 Blocking: Cancer cells often use the PD-L1/L2 ligands to bind to the PD-1 receptors on T-cells, effectively “turning off“ the immune response. Immune Re-Activation: Tislelizumab binds specifically to the PD-1 receptor, preventing cancer cells from deactivating T-cells. Restoring T-Cell Function: By removing this molecular “blindfold,“ the immune system can recognize the tumor as a threat and initiate a natural attack. Fc-Engineered Design: Tevimbra is specifically engineered to minimize binding to Fcγ receptors on macrophages, which is believed to help prevent the unintended depletion of T-cells, potentially enhancing anti-tumor activity. Dosage and Administration Guidelines Standard Dosage: The typical dose is 200mg (two 100mg vials) administered every 3 weeks. Alternate Schedules: Some protocols allow for 400mg every 6 weeks, depending on the specific cancer type and patient response. Administration Method: Delivered via intravenous (IV) infusion. The initial infusion usually lasts 60 minutes. If tolerated well, subsequent infusions may be shortened to 30 minutes. Clinical Environment: Must be administered by a qualified healthcare professional in a hospital or specialized oncology center. Safety Profile and Expert Monitoring As an immunotherapy, Tevimbra can cause the immune system to become overactive. Professional monitoring is essential for: Immune-Mediated Adverse Reactions: Potential inflammation of the lungs (pneumonitis), liver (hepatitis), colon (colitis), or hormone glands (endocrinopathies). Common Side Effects: Fatigue, musculoskeletal pain, decreased appetite, cough, and anemia. Laboratory Monitoring: Regular blood tests to check liver function, thyroid levels, and blood counts are required throughout the treatment cycle. Precautions: Not recommended for use during pregnancy or breastfeeding due to potential embryo-fetal toxicity. Storage and Handling: The Cold-Chain Requirement Temperature Control: Tevimbra is a sensitive biological product and MUST be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Global Transit: For international export, we utilize validated cold-chain packaging and real-time temperature data loggers to ensure product integrity remains at 100% until it reaches the destination. Handling: Do not freeze or shake the vials. Keep them in the original carton to protect them from light. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Brukinsa 80mg Capsule (Zanubrutinib): Next-Generation BTK Inhibitor for B-Cell Malignancies Brukinsa 80mg Capsule is a highly potent, small-molecule inhibitor of Bruton’s Tyrosine Kinase (BTK), featuring the active pharmaceutical ingredient Zanubrutinib. Developed by BeiGene, Brukinsa represents a significant evolution in targeted therapy for B-cell cancers. It is engineered to provide maximized BTK occupancy and minimized off-target binding, leading to superior efficacy and a more favorable safety profile compared to first-generation inhibitors. Therapeutic Indications and Clinical Usage Brukinsa 80mg is a preferred therapeutic agent in global oncology protocols for several types of blood cancers: Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Indicated for adult patients as both first-line therapy and for relapsed or refractory cases. Waldenström’s Macroglobulinemia (WM): Used as a primary treatment for adult patients with this rare type of B-cell lymphoma. Mantle Cell Lymphoma (MCL): Prescribed for adult patients who have received at least one prior therapy. Marginal Zone Lymphoma (MZL): Indicated for adult patients with relapsed or refractory MZL who have received at least one anti-CD20-based regimen. Follicular Lymphoma (FL): In combination with obinutuzumab for adult patients with relapsed or refractory follicular lymphoma after at least two lines of systemic therapy. Mechanism of Action: How Brukinsa 80mg Works Brukinsa functions through precise molecular targeting of the B-cell receptor signaling pathway: BTK Inhibition: Bruton’s Tyrosine Kinase (BTK) is a critical signaling protein necessary for the development, activation, and survival of B-lymphocytes. Covalent Binding: Zanubrutinib forms a strong, covalent bond with a specific cysteine residue in the BTK active site. Pathway Blockade: By inhibiting BTK, Brukinsa effectively shuts down the signaling pathways that tell malignant B-cells to proliferate and survive. High Selectivity: Unlike earlier treatments, Brukinsa is designed to be highly selective, meaning it is less likely to inhibit other kinases (like ITK or EGFR), which helps reduce side effects like atrial fibrillation and bleeding. Dosage and Administration Guidelines Standard Dosage: The recommended total daily dose is 320 mg, which can be administered as either 160 mg (two 80 mg capsules) twice daily or 320 mg (four 80 mg capsules) once daily. Administration: Capsules should be swallowed whole with water. Do not open, crush, or chew the capsules. Consistency: Can be taken with or without food. Maintain a consistent schedule to ensure steady therapeutic levels. Dose Modification: Oncologists may adjust the dosage for patients with severe hepatic impairment or those taking certain medications that interact with the CYP3A enzyme. Safety Profile and Professional Monitoring Treatment with Brukinsa 80 mg requires ongoing clinical assessment to manage potential risks: Hemorrhage Risk: Patients should be monitored for signs of bleeding. Treatment may need to be suspended before and after surgical procedures. Cardiac Health: While rare with Zanubrutinib, monitoring for atrial fibrillation and flutter is recommended, especially in patients with existing cardiac risk factors. Cytopenias: Regular Complete Blood Counts (CBC) are necessary to monitor for neutropenia, thrombocytopenia, and anemia. Infection Control: Patients may be at an increased risk of infections, including pneumonia or upper respiratory tract infections. Storage and Global Handling Requirements Temperature: Store at room temperature, 20°C to 25°C (68°F to 77°F). Protection: Keep the bottle tightly closed and protected from excessive moisture. Safety: Always keep out of reach of children and pets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Imfinzi 500mg Injection (Durvalumab): Advanced PD-L1 Immunotherapy for Complex Malignancies Imfinzi 500mg Injection is a potent, high-concentration biological therapy containing the active substance. Durvalumab. It is a programmed death-ligand 1 (PD-L1) blocking antibody, representing the forefront of modern oncology. Manufactured by AstraZeneca, the 500 mg vial is the high-dose format designed for precision administration in clinical settings to treat aggressive cancers by re-engineering the body's natural immune response. Therapeutic Indications and Clinical Usage Imfinzi 500 mg is a cornerstone in international oncology protocols for several life-threatening malignancies: Non-Small Cell Lung Cancer (NSCLC): Indicated as a maintenance therapy for adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Small Cell Lung Cancer (SCLC): Used as a first-line treatment in combination with etoposide and either carboplatin or cisplatin for adult patients with extensive-stage small cell lung cancer (ES-SCLC). Biliary Tract Cancer (BTC): Employed in combination with chemotherapy (gemcitabine and cisplatin) for locally advanced or metastatic biliary tract cancer. Hepatocellular Carcinoma (HCC): Indicated for unresectable liver cancer, often in combination with other immunotherapies like tremelimumab. Mechanism of Action: How Imfinzi 500mg Works Imfinzi functions as an immune checkpoint inhibitor, specifically targeting the PD-1/PD-L1 pathway: PD-L1 Blockade: Cancer cells often produce PD-L1 proteins to “mask“ themselves from the immune system. When PD-L1 binds to T-cells, it sends a signal for the T-cell to remain inactive. Immune Liberation: Durvalumab binds directly to PD-L1, preventing it from interacting with PD-1 and CD80 receptors on T-cells. T-Cell Activation: By removing this “brake,“ Imfinzi allows the patient’s T-cells to recognize, target, and destroy the malignant cells throughout the body. Durable Defense: Because it works with the immune system, the treatment can create a “memory“ effect, leading to prolonged survival and long-term remission in many patients. Dosage and Administration Guidelines Route of Administration: Imfinzi 500 mg is administered via intravenous (IV) infusion only. Infusion Process: The procedure typically takes 60 minutes and must be performed by healthcare professionals in a specialized oncology unit. Calculation: Dosage is calculated based on the patient’s body weight (e.g., 10 mg/kg or 1500 mg fixed dose) and the specific treatment cycle (every 2, 3, or 4 weeks). Vial Strength: The 500 mg vial is often used in combination with 120 mg vials to achieve the exact required dose for larger patients or specific maintenance schedules. Safety Profile and Professional Monitoring As a potent immunotherapy, Imfinzi 500mg requires vigilant medical oversight to manage immune-mediated adverse reactions: Organ Inflammation: The immune system may inadvertently attack healthy organs, leading to immune-mediated pneumonitis (lungs), colitis (intestines), hepatitis (liver), or endocrinopathies (hormonal glands). Infusion-Related Reactions: Patients may experience fever, chills, or respiratory distress during administration. Common Side Effects: These include cough, fatigue, hair loss (when used with chemo), and nausea. Mandatory Testing: Patients must undergo regular blood tests, liver function tests, and thyroid monitoring before each infusion. Strict Cold-Chain Storage & Global Handling Temperature Sensitivity: Imfinzi is a biologic and MUST be stored under strict refrigeration between 2°C and 8°C (36°F to 46°F). Handling: Do not freeze. Do not shake the vial. Keep the vial in its original carton to protect it from light. Transit Security: For global export, specialized thermal packaging and data loggers are used to ensure the cold chain is never broken during international flight or transit. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Imfinzi 120mg Injection (Durvalumab): Advanced PD-L1 Cancer Immunotherapy Guide Imfinzi 120 mg Injection is a high-precision biological medication containing the active ingredient Durvalumab. It is a human monoclonal antibody that belongs to a revolutionary class of cancer treatments known as immune checkpoint inhibitors. Manufactured by AstraZeneca, Imfinzi 120mg is engineered to reactivate the patient’s own immune system to identify and eliminate cancer cells, offering a sophisticated alternative or supplement to traditional chemotherapy. Therapeutic Indications and Clinical Usage Imfinzi 120 mg is a cornerstone in international oncology protocols for the treatment of several aggressive malignancies: Non-Small Cell Lung Cancer (NSCLC): Specifically indicated for adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. Small Cell Lung Cancer (SCLC): Used in combination with etoposide and either carboplatin or cisplatin as a first-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC). Biliary Tract Cancer (BTC): In combination with gemcitabine and cisplatin for the treatment of adult patients with locally advanced or metastatic biliary tract cancer. Hepatocellular Carcinoma (HCC): Used in combination with tremelimumab for the treatment of adult patients with unresectable hepatocellular carcinoma. Mechanism of Action: How Imfinzi 120mg Works Imfinzi functions by targeting the molecular “brakes“ that cancer cells use to hide from the immune system: PD-L1 Blockade: Many cancer cells express a protein called PD-L1 (Programmed Death-Ligand 1). This protein binds to receptors on T-cells (the body's primary immune soldiers), effectively “turning them off“ and allowing the tumor to grow undetected. Immune Re-Activation: Durvalumab binds specifically to the PD-L1 protein, blocking its interaction with PD-1 and CD80. Tumor Destruction: By removing this blockade, Imfinzi releases the “brakes“ on the T-cells, empowering them to recognize, attack, and destroy the malignant cells. Long-Term Response: Because it utilizes the immune system, Imfinzi can often lead to durable, long-lasting clinical responses even after treatment is completed. Dosage and Administration Guidelines Route of Administration: Imfinzi 120 mg is administered as an intravenous (IV) infusion. It is never injected as a bolus or push. Infusion Duration: Each infusion typically lasts approximately 60 minutes. Dosing Schedule: The frequency (e.g., every 2, 3, or 4 weeks) and total dosage depend entirely on the specific type of cancer being treated and the patient's body weight. Clinical Supervision: Administration must occur in a hospital or clinical setting under the direct supervision of an oncology specialist equipped to manage infusion-related reactions. Safety Profile and Professional Monitoring As a potent immunotherapy, Imfinzi 120mg requires vigilant medical oversight to manage immune-mediated adverse reactions: Immune-Mediated Organ Inflammation: Imfinzi can cause the immune system to attack healthy organs. This can lead to pneumonitis (lungs), colitis (intestines), hepatitis (liver), or endocrinopathies (hormone glands). Infusion Reactions: Patients may experience chills, shaking, or dizziness during the infusion. Common Side Effects: Fatigue, musculoskeletal pain, constipation, and decreased appetite are frequently reported. Monitoring: Regular blood chemistry tests, thyroid function tests, and physical assessments are mandatory throughout the treatment duration. Storage and Global Handling Requirements Cold Chain Management: Imfinzi is a temperature-sensitive biologic. It MUST be stored under refrigeration at 2°C to 8°C (36°F to 46°F). Handling: Do not freeze or shake the vial. Protect it from light by keeping it in the original carton. Transportation: For global export, specialized cold-chain logistics are required to ensure the vial remains within the required temperature range from our facility to your clinic Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Brcaone 150mg Tablet (Olaparib): Precision PARP Inhibitor for Targeted Oncology Care Brcaone 150mg Tablet is a specialized, targeted anti-cancer medication featuring the active ingredient Olaparib. It belongs to a revolutionary class of drugs known as PARP (poly [adenosine diphosphate-ribose] polymerase) inhibitors. Manufactured by Bresure Care, Brcaone 150mg represents a breakthrough in precision medicine, specifically engineered to exploit genetic vulnerabilities in cancer cells—particularly those with BRCA mutations—to induce “synthetic lethality.“ Therapeutic Indications and Clinical Usage Brcaone 150mg is utilized globally for the management of advanced malignancies, specifically targeting cancers associated with BRCA1/BRCA2 gene mutations and homologous recombination repair (HRR) deficiencies: Advanced Ovarian Cancer: Used as a maintenance treatment for adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. HER2-Negative Metastatic Breast Cancer: Indicated for the treatment of adult patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have been previously treated with chemotherapy.Metastatic Pancreatic Cancer: Employed for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Metastatic Castration-Resistant Prostate Cancer (mCRPC): Prescribed for patients with specific HRR gene-mutated mCRPC who have progressed following prior treatment with enzalutamide or abiraterone. Mechanism of Action: How Brcaone 150mg Works Enzyme Inhibition: PARP enzymes are essential for repairing single-strand breaks in DNA. Brcaone binds to and inhibits these enzymes. DNA Damage Accumulation: When PARP is blocked, single-strand DNA breaks transition into double-strand breaks during cell replication. Synthetic Lethality: In cancer cells with existing DNA repair deficiencies (like BRCA1/2 mutations), these double-strand breaks cannot be repaired, leading to genomic instability and programmed cell death (apoptosis). Selective Targeting: Because healthy cells have intact alternative DNA repair pathways, they are significantly less affected by Brcaone than cancerous ones, reducing systemic damage. Dosage and Administration Guidelines Standard Dosage: The typical adult dose is 300mg (two 150mg tablets) taken twice daily, totaling 600mg per day. Method of Intake: Tablets must be swallowed whole with water. They should not be chewed, crushed, dissolved, or divided. Timing: Can be taken with or without food. It is recommended to take doses approximately 12 hours apart to maintain steady therapeutic levels. Clinical Adjustments: Dosage may be modified by an oncologist based on individual patient tolerance, renal function, or to manage specific adverse reactions. Safety Profile and Professional Monitoring Hematological Monitoring: Common side effects include anemia, neutropenia (low white blood cells), and thrombocytopenia (low platelets). Regular Complete Blood Counts (CBC) are required before and during treatment. Gastrointestinal Support: Nausea, vomiting, and diarrhea are frequently reported. These are managed with supportive care and adequate hydration. Respiratory Vigilance: Patients should report any new or worsening shortness of breath or cough, as inflammation of the lungs (pneumonitis) can occur in rare cases. Embryo-Fetal Toxicity: Olaparib can cause fetal harm. Effective contraception is mandatory for both male and female patients of reproductive potential during treatment. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep tablets in the original container to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the tablets. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celnalid 5mg Capsule (Lenalidomide): Low-Dose Precision Immunomodulatory Therapy: Celnalid 5mg capsule is a specialized anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 5 mg strength is a critical dosage form used primarily for maintenance therapy, dose tapering, and patients requiring renal dose adjustments. Manufactured by Celon Laboratories Pvt. Ltd., Celnalid 5mg is an essential component in the long-term management of hematological malignancies, providing a balance between therapeutic efficacy and manageable toxicity. Therapeutic Indications and Clinical Usage Celnalid 5 mg is extensively utilized across international oncology protocols for: Multiple Myeloma (MM) Maintenance: Following an autologous stem cell transplant (ASCT) or induction therapy, the 5 mg dose is often used as a long-term maintenance strategy to prevent disease relapse. Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Renal Dose Adjustments: For patients with moderate to severe renal impairment, the 5 mg capsule allows for precise dosing to maintain efficacy while reducing the risk of systemic toxicity. Relapsed/Refractory Lymphoma: Used in combination with other agents for patients with Mantle Cell Lymphoma (MCL) or Follicular Lymphoma who require a lower starting dose or a dose reduction. Mechanism of Action: How Celnalid 5 mg Works Even at a lower 5 mg concentration, Lenalidomide exerts a potent multi-pathway biological effect: Cereblon Binding: It binds to the protein Cereblon, part of the E3 ubiquitin ligase complex, leading to the selective degradation of transcription factors (Ikaros and Aiolos) necessary for cancer cell survival. Anti-Angiogenesis: It blocks the secretion of pro-angiogenic factors (like VEGF), preventing the tumor from forming the new blood vessels it needs to grow. Immune Surveillance: It enhances the activity of T-cells and Natural Killer (NK) cells, boosting the body’s innate ability to find and destroy residual cancer cells. Cytokine Modulation: It inhibits the production of pro-inflammatory cytokines like TNF-$alpha$, which otherwise support the survival of malignant cells in the bone marrow microenvironment. Dosage and Administration Guidelines Maintenance Dosing: In maintenance settings, Celnalid 5 mg is often taken once daily on a continuous basis or following a “21 days on, 7 days off“ cycle. Administration: Capsules must be swallowed whole with water. They should not be opened, crushed, or chewed. Consistency: Can be taken with or without food, but should be taken at a consistent time each day to maintain steady-state plasma concentrations. Dose Escalation/De-escalation: The 5 mg strength provides oncologists with the flexibility to titrate the dose upward as tolerated or downward to manage hematological toxicities. Safety Profile and Clinical Monitoring Low-dose therapy still requires vigilant professional oversight: Hematological Monitoring: Regular Complete Blood Counts (CBC) are required to monitor for neutropenia and thrombocytopenia, though these are typically less frequent at the 5 mg level than at higher doses. Thromboembolism Prophylaxis: Even at 5mg, there remains a risk of blood clots (DVT/PE). Anticoagulant therapy (e.g., Aspirin) is frequently continued during maintenance. Embryo-Fetal Toxicity (REMS): Lenalidomide remains a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients regardless of dosage. General Side Effects: Patients may experience mild fatigue, diarrhea, or skin rashes. Storage and Global Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Original Packaging: Keep the capsules in the original blister pack to protect them from moisture and light. Safety: Caregivers should avoid direct skin contact with the medication; if a capsule is broken, wash the area immediately. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celnalid 25mg Capsule (Lenalidomide): High-Potency Immunotherapy for Advanced Oncology Celnalid 25 mg Capsule is a high-strength anti-cancer medication featuring the active pharmaceutical ingredient lenalidomide. Classified as an immunomodulatory imide drug (IMiD), the 25 mg strength is primarily utilized during the intensive induction phase of treatment for various hematological malignancies. Manufactured by Celon Laboratories Pvt. Ltd., Celnalid 25mg is a critical therapeutic intervention designed to disrupt cancer cell proliferation while enlisting the body's natural immune defenses. Therapeutic Indications and Clinical Usage Celnalid 25 mg is utilized across major international oncology protocols for Multiple Myeloma (MM): Used as a first-line therapy (typically in combination with Dexamethasone) for newly diagnosed patients and as a primary treatment for relapsed or refractory cases. Mantle Cell Lymphoma (MCL): Indicated for patients whose disease has progressed or relapsed after at least two prior therapies, including one involving a proteasome inhibitor. Myelodysplastic Syndromes (MDS): Specifically for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Follicular Lymphoma (FL): Often used in combination with Rituximab for adult patients previously treated for follicular or marginal zone lymphoma.Mechanism of Action: How Celnalid 25mg Works The efficacy of Celnalid 25 mg stems from its multi-pronged biological approach: Direct Tumoricidal Effect: It induces cell cycle arrest and triggers apoptosis (programmed cell death) specifically in malignant hematopoietic cells. Immune System Enhancement: It stimulates T-cells and Natural Killer (NK) cells, significantly increasing the body’s innate ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the formation of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply, effectively “starving“ the tumor. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-$alpha$ and IL-6, which otherwise promote the growth of myeloma cells in the bone marrow. Dosage and Administration Guidelines Intensive Dosing: The 25 mg strength is typically the starting dose for many multiple myeloma regimens, often taken once daily on Days 1–21 of a 28-day cycle. Administration: Capsules must be swallowed whole with water. Do not open, crush, or chew them. Timing: Can be taken with or without food, but should be taken at a consistent time each day to maintain therapeutic plasma levels. Dose Adjustments: Physicians may reduce the dose from 25 mg to lower strengths (15 mg, 10 mg, or 5 mg) based on patient tolerance, renal function, or during the maintenance phase of therapy. Safety Profile and Clinical Monitoring Due to its high potency, Celnalid 25mg requires strict medical supervision: Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Most patients are prescribed blood thinners (anticoagulants) concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients. Common Side Effects: Fatigue, diarrhea, muscle cramps, and skin rashes are frequently reported and managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should handle the capsules with care; avoid skin contact if a capsule is accidentally broken. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Celomide 25mg Capsule (Lenalidomide): High-Potency Immunomodulatory Therapy for Oncology CareCelomide 25mg Capsule is a high-strength anti-cancer medication featuring the active pharmaceutical ingredient Lenalidomide. As a primary immunomodulatory imide drug (IMiD), the 25 mg strength represents the intensive induction phase dosage used globally to treat aggressive hematological malignancies. Manufactured by Celon Laboratories Pvt. Ltd., Celomide 25mg is a cornerstone in precision oncology, designed to disrupt cancer cell proliferation while enlisting the body's natural immune defenses. Therapeutic Indications and Clinical Usage Celomide 25 mg is utilized across major international oncology protocols for: Multiple Myeloma (MM): Used as first-line therapy (in combination with Dexamethasone) for newly diagnosed patients and as a primary treatment for relapsed or refractory cases. Mantle Cell Lymphoma (MCL): Indicated for patients whose disease has progressed or relapsed after at least two prior therapies. Myelodysplastic Syndromes (MDS): Specifically for transfusion-dependent anemia due to low- or intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality. Follicular Lymphoma (FL): Often used in combination with Rituximab for previously treated adult patients.Mechanism of Action: How Celomide 25mg WorksThe efficacy of Celomide 25mg stems from its multi-pronged biological approach:Direct Tumoricidal Effect: It induces cell cycle arrest and triggers apoptosis (programmed cell death) specifically in malignant hematopoietic cells.Immune System Enhancement: It stimulates T-cells and Natural Killer (NK) cells, significantly increasing the body’s innate ability to identify and eliminate tumor cells. Anti-Angiogenesis: It inhibits the formation of new blood vessels (angiogenesis) that tumors require for oxygen and nutrient supply, effectively “starving“ the tumor. Cytokine Regulation: It suppresses the production of pro-inflammatory cytokines such as TNF-$alpha$ and IL-6, which otherwise promote the growth of myeloma cells. Dosage and Administration Guidelines Intensive Dosing: The 25 mg strength is typically the starting dose for many multiple myeloma regimens, often taken once daily on Days 1–21 of a 28-day cycle. Administration: Capsules must be swallowed whole with water. Do not open, crush, or chew them. Timing: Can be taken with or without food, but should be taken at a consistent time each day to maintain therapeutic plasma levels. Dose Adjustments: Physicians may reduce the dose from 25 mg to lower strengths (15 mg, 10 mg, or 5 mg) based on patient tolerance, renal function, or during the maintenance phase.Safety Profile and Clinical Monitoring Due to its high potency, Celomide 25mg requires strict medical supervision: Hematological Vigilance: Regular Complete Blood Counts (CBC) are mandatory to monitor for neutropenia (low white blood cells) and thrombocytopenia (low platelets). Thromboembolism Prophylaxis: There is an increased risk of blood clots (DVT/PE). Most patients are prescribed blood thinners (anticoagulants) concurrently. Embryo-Fetal Toxicity (REMS): Lenalidomide is a known teratogen. Strict adherence to pregnancy prevention programs (REMS) is mandatory for all patients. Common Side Effects: Fatigue, diarrhea, muscle cramps, and skin rashes are frequently reported and managed with supportive care. Storage and Handling Instructions Temperature: Store at room temperature, 20°C to 25°C. Protection: Keep capsules in the original blister packaging to protect from light and moisture. Safety: Caregivers should handle the capsules with care; avoid skin contact if a capsule is accidentally broken. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383